Greetings from MyCancerHaven!
We wanted to update you on our recent activities.
We've added below videos to our Videos repository.
The video is titled
Isatuximab:For Front-line Transplant Ineligible Patients by Adriana Rossi MD from Assistant Professor Director CAR-T and Stem Cell Transplant Clinical Program Mt Sinai Hospital New York , and it's been added/updated in Multiple Myeloma Category
Isatuximab:For Front-line Transplant Ineligible Patients by Adriana Rossi MD from Assistant Professor Director CAR-T and Stem Cell Transplant Clinical Program Mt Sinai Hospital New York , and it's been added/updated in Multiple Myeloma Category
Here are the latest posts last week:
Blogs :
Using Absolute Lymphocyte Count to Predict Outcomes After CAR T-Cell Therapy
Dr. Martin Highlights Recent Advances in Myeloma Research at EHA 2024
Pesticides as big a cancer risk as smoking
Podcast: Putting Patients First
Should Autologous Stem Cell Transplantation Be Considered for Older Myeloma Patients?
US Cancer Survivor Population Projected to Reach 26 Million by 2040
Current Studies on CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma
Sequencing BCMA-Targeting Bispecifics and CAR-T Therapies in Relapsed/Refractory MM
Should Minimal Residual Disease Inform Therapy Decisions for Multiple Myeloma Patients?
Issues With Prior Authorization Result In Patients Forgoing Care
"Keep your face to the sunshine and you cannot see a shadow."
The Changing Treatment Landscape for Relapsed/Refractory Multiple Myeloma
Dr. Siegel on the Importance of Achieving Durable Remissions in Patients with Multiple Myeloma
Dr. Landgren on the Management of Treatment for Newly Diagnosed Multiple Myeloma
Cilta-cel in Relapsed/Refractory MM: ASCO 2024 Updates from CARTITUDE Trials
Benefits of Using CAR-T Therapy in Later Lines for Multiple Myeloma
Addressing Unmet Needs in the Management of Relapsed/Refractory Multiple Myeloma
The Role of Stem Cell Transplantation in Relapsed/Refractory Multiple Myeloma
Few Patients With Multiple Myeloma Meet Physical Activity Recommendations
Dr. Facon on the Implications of Isatuximab Plus VRd in Transplant-Ineligible Newly Diagnosed MM
Also at MCH the News and Tweets never stop flowing!
Join Us at www.mycancerhaven.org
The Team @ MCH
Follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok
Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org.
We wanted to update you on our recent activities.
We've added below videos to our Videos repository.
The video is titled
Isatuximab:For Front-line Transplant Ineligible Patients by Adriana Rossi MD from Assistant Professor Director CAR-T and Stem Cell Transplant Clinical Program Mt Sinai Hospital New York , and it's been added/updated in Multiple Myeloma Category
Isatuximab:For Front-line Transplant Ineligible Patients by Adriana Rossi MD from Assistant Professor Director CAR-T and Stem Cell Transplant Clinical Program Mt Sinai Hospital New York , and it's been added/updated in Multiple Myeloma Category
Here are the latest posts last week:
Blogs :
Using Absolute Lymphocyte Count to Predict Outcomes After CAR T-Cell Therapy
Dr. Martin Highlights Recent Advances in Myeloma Research at EHA 2024
Pesticides as big a cancer risk as smoking
Podcast: Putting Patients First
Should Autologous Stem Cell Transplantation Be Considered for Older Myeloma Patients?
US Cancer Survivor Population Projected to Reach 26 Million by 2040
Current Studies on CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma
Sequencing BCMA-Targeting Bispecifics and CAR-T Therapies in Relapsed/Refractory MM
Should Minimal Residual Disease Inform Therapy Decisions for Multiple Myeloma Patients?
Issues With Prior Authorization Result In Patients Forgoing Care
"Keep your face to the sunshine and you cannot see a shadow."
The Changing Treatment Landscape for Relapsed/Refractory Multiple Myeloma
Dr. Siegel on the Importance of Achieving Durable Remissions in Patients with Multiple Myeloma
Dr. Landgren on the Management of Treatment for Newly Diagnosed Multiple Myeloma
Cilta-cel in Relapsed/Refractory MM: ASCO 2024 Updates from CARTITUDE Trials
Benefits of Using CAR-T Therapy in Later Lines for Multiple Myeloma
Addressing Unmet Needs in the Management of Relapsed/Refractory Multiple Myeloma
The Role of Stem Cell Transplantation in Relapsed/Refractory Multiple Myeloma
Few Patients With Multiple Myeloma Meet Physical Activity Recommendations
Dr. Facon on the Implications of Isatuximab Plus VRd in Transplant-Ineligible Newly Diagnosed MM
Also at MCH the News and Tweets never stop flowing!
Join Us at www.mycancerhaven.org
The Team @ MCH
Follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok
Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org.
